Elliott D S, Blute M L, Patterson D E, Bergstralh E J, Segura J W
Department of Urology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Urology. 1996 Jun;47(6):819-25. doi: 10.1016/S0090-4295(96)00043-X.
This report focuses on the long-term follow-up of patients with endoscopically treated upper tract transitional cell carcinoma (TCC) to determine the effectiveness of endoscopic therapy.
From May 1983 to April 1994, 44 patients with TCC of the upper urinary tract underwent conservative endourologic treatment with either electrocautery fulguration or neodymium:yttrium-aluminum-garnet laser at our institution. The mean follow-up period was 5 years (range, 3 months to 11 years).
Renal pelvic tumor sizes ranged from 0.4 to 4.0 cm (mean, 1.5) and ureteral tumors from 0.2 to 1.0 cm (mean, 0.5). The majority of tumors were of pathologic grade 3 or less, and all were Stage T2 or less. Seventeen of 44 patients (38.6%) had local tumor recurrence (mean time to recurrence, 12.8 months; range 1.5 to 64). Mean recurrence time was 7.3 months for renal pelvic tumors and 17.8 months for ureteral tumors. Nineteen of 44 patients (43.2%) developed bladder tumors. The overall 5-year disease-free rate was 57%. No recurrent tumor was shown to have increased in grade, and one recurrent tumor was proved to have progressed in stage. Six patients (14%) ultimately required a nephroureterectomy for recurrence. There were no major complications as a result of endoscopic therapy. Six patients (14%) died of the effects of metastatic TCC, 5 of whom had known muscle invasive bladder TCC.
Endourologic techniques and the conservative treatment of upper urinary tract TCC is an evolving field and can be safely and effectively used as a first-line treatment for upper tract TCC in selected patients.
本报告聚焦于经内镜治疗的上尿路移行细胞癌(TCC)患者的长期随访,以确定内镜治疗的有效性。
1983年5月至1994年4月,44例上尿路TCC患者在我院接受了保守性腔内泌尿外科治疗,采用电灼凝固术或钕:钇铝石榴石激光治疗。平均随访期为5年(范围3个月至11年)。
肾盂肿瘤大小为0.4至4.0厘米(平均1.5厘米),输尿管肿瘤为0.2至1.0厘米(平均0.5厘米)。大多数肿瘤病理分级为3级或更低,且均为T2期或更低。44例患者中有17例(38.6%)出现局部肿瘤复发(平均复发时间12.8个月;范围1.5至64个月)。肾盂肿瘤平均复发时间为7.3个月,输尿管肿瘤为17.8个月。44例患者中有19例(43.2%)发生膀胱肿瘤。总体5年无病生存率为57%。未发现复发性肿瘤分级增加,且有1例复发性肿瘤被证实分期进展。6例患者(14%)最终因复发需要行肾输尿管切除术。内镜治疗未导致重大并发症。6例患者(14%)死于转移性TCC的影响,其中5例已知有肌肉浸润性膀胱TCC。
腔内泌尿外科技术及上尿路TCC的保守治疗是一个不断发展的领域,在部分患者中可安全有效地用作上尿路TCC的一线治疗方法。